Some studies reported that knockdown of FOXO3a led to expansion of the CSC population as well as increased self-renewal and tumorigenic capacity in lung and breast cancer [17, 18, 21], and that FOXO3a activation could inhibit CSC properties and tumor initiation in colorectal cancer [20]. This evidence concerns the gene FOXO3 and breast carcinoma.